Latest Working Capital News

Morella Corporation has locked in A$1.4 million in convertible note funding from key shareholders and directors, strengthening its financial position to advance critical minerals exploration and acquisitions.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

Avira Resources has secured a binding agreement to acquire the high-grade Mt Cattlin Gold Project in Western Australia, backed by a $2.5 million capital raise to advance exploration and resource development.

Audio Pixels Holdings has extended the maturity of $12.3 million in convertible notes to January 2027 and capitalised $4.05 million in accrued interest, enhancing its financial flexibility.

EV Resources has secured a 150-tonne-per-day processing plant near its Los Lirios project, fast-tracking antimony production and positioning itself as a key North American supplier.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Scout Security has raised a further $220,000 through a share placement, bringing total capital raised to $820,000, as it works toward resolving its trading suspension.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Australian Strategic Materials secures A$50.8 million via share placement to fund Korean plant expansion and advance US metals project, while navigating complex supply chain and funding risks.

Horizon Gold advances its Gum Creek project with significant gold intercepts from water bore drilling and launches an AI-powered exploration platform, while maintaining its feasibility study timeline and securing $12 million in fresh capital.

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.

Magmatic Resources has successfully raised A$3 million through a discounted placement, with major shareholder FMG Resources increasing its stake to nearly 20%. The funds will accelerate exploration at key copper and gold projects.